MCB-22-174 is a potent agonist of Piezo1, with an EC50 value of 6.28 µM. It activates the Ca2+-related extracellular signal-related kinases and calcium–calmodulin (CaM)-dependent protein kinase II (CaMKII) pathway and promotes mesenchymal stem cells osteoblastic differentiation, exhibiting its potential use in research for the treatment of disuse osteoporosis (OP).

MCB-22-174 is a potent agonist of Piezo1, with an EC50 value of 6.28 µM. It activates the Ca2+-related extracellular signal-related kinases and calcium–calmodulin (CaM)-dependent protein kinase II (CaMKII) pathway and promotes mesenchymal stem cells osteoblastic differentiation, exhibiting its potential use in research for the treatment of disuse osteoporosis (OP).

MCB-22-174 is a potent agonist of Piezo1, with an EC50 value of 6.28 µM. It activates the Ca2+-related extracellular signal-related kinases and calcium–calmodulin (CaM)-dependent protein kinase II (CaMKII) pathway and promotes mesenchymal stem cells osteoblastic differentiation, exhibiting its potential use in research for the treatment of disuse osteoporosis (OP).

MCB-22-174 is a potent agonist of Piezo1, with an EC50 value of 6.28 µM. It activates the Ca2+-related extracellular signal-related kinases and calcium–calmodulin (CaM)-dependent protein kinase II (CaMKII) pathway and promotes mesenchymal stem cells osteoblastic differentiation, exhibiting its potential use in research for the treatment of disuse osteoporosis (OP).

Amelenodor (NX-13) is an orally available, gut-selective molecule that activates the mitochondrial receptor NLRX1 to reduce intestinal inflammation. It promotes oxidative phosphorylation while suppressing proinflammatory pathways like Th1/Th17 differentiation and cytokine production. It has the potential to treat inflammatory bowel disease (IBD).

Amelenodor (NX-13) is an orally available, gut-selective molecule that activates the mitochondrial receptor NLRX1 to reduce intestinal inflammation. It promotes oxidative phosphorylation while suppressing proinflammatory pathways like Th1/Th17 differentiation and cytokine production. It has the potential to treat inflammatory bowel disease (IBD).

Amelenodor (NX-13) is an orally available, gut-selective molecule that activates the mitochondrial receptor NLRX1 to reduce intestinal inflammation. It promotes oxidative phosphorylation while suppressing proinflammatory pathways like Th1/Th17 differentiation and cytokine production. It has the potential to treat inflammatory bowel disease (IBD).